Ciplas antiviral drug Cipremi to be used to treat COVID-19 infection

Cipla Ltd has announced the launch of its generic version of antiviral drug Remdesivir for emergency use in the treatment of the COVID-19 patients.
The new drug will be sold under the brand name Cipremi. Cipla’s antiviral drug Cipremi will join Glenmark’s Fabiflu and Hetero’s Covifor to treat the COVID-19 patients in India.
Cipla was granted regulatory approval by the Drug Controller General of India (DCGI) for restricted emergency use in the country in order to accelerate the approval process considering the urgent medical need with a surge in COVID-19 cases in India, which have crossed the 4,00,000-mark.
The price of the drug is yet to be announced by Cipla.
Cipla will provide training on the use of the drug, inform patients for consent documents, conduct post-marketing surveillance as well as to conduct a Phase-IV clinical trial on Indian patients.
Remdesivir is the only USFDA approved Emergency Use Authorisation (EUA) treatment for adults and children hospitalized with suspected or laboratory-confirmed coronavirus infection.